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47
Genomic epidemiology has provided novel insights into the genetic characteristics and 48 phylogenetic diversity of botulinum neurotoxin (BoNT)-producing Clostridium species (1-8). 49 BoNT are responsible for causing the serious paralytic disease botulism and their potent 50 neuro-paralytic activity make them one of the top, Tier 1, agents considered to pose a 51 significant threat to public health if used for bioterrorism (Electronic Code of Federal 52 Regulations -Title 42; Part 73: http://www.ecfr.gov/cgi-53 bin/retrieveECFR?r=PART&n=42y1.0.1.6.61) (9, 10). The same properties also make them a 54 powerful tool for both medical therapeutic and cosmetic applications (11). 55 Botulism is a very rare disease in Australia (National Notifiable Diseases Surveillance System: 56 NNDSS-http://www9.health.gov.au/cda/source/cda-index.cfm), with only twenty cases 57 reported since 1991. However, a global survey found that Australia had one of the highest 58 numbers of notified cases of infant botulism in the world (12, 13) . Infant botulism results 59 from the ingestion of Clostridium botulinum spores which germinate and temporarily 60 colonise the infant's colon and vegetative cells begin to grow and produce . 61 This form of the disease only occurs in infants, generally under one year old, as they have 62 relatively low levels of gastric acid and poorly developed normal gut microflora (17). It is 63 epidemiologically distinct from foodborne botulism which results from the ingestion of 64 preformed BoNT from contaminated food (18) 65 (http://www.cdc.gov/ncidod/dbmd/diseaseinfo/files/botulism.PDF).
66
The first clinical signs in infant botulism are usually constipation and lethargy, with 67 progression to poor feeding, muscular weakness, abnormal eye movements and, in the 68 absence of intervention, progressive symmetrical flaccid paralysis and respiratory arrest due 69 to neuromuscular junction blockage (19, 20) . A number of risk factors have been identified, 70 including the consumption of honey (21-24), herbal infusions (25), contamination of infant 71 food such as powdered formula (26), exposure to household dust (27) and disrupted soil 72 (20, 28) . Contact with pet terrapins has also recently been identified as a risk factor for 73 infant botulism caused by Clostiridium butyricum producing BoNT/E (29). However, sources 74 of infection or specific risk factors have generally not been identified for either sporadic or 75 clustered cases (30) . Infant botulism has a low mortality rate but can be associated with 76 significant morbidity. However, the timely administration of Human Botulism Immune 77 Globulin Intravenous (BIG-IV) has been shown to reduce morbidity, as evidenced by a 78 significant reduction in the mean length of hospital stay (19, 20, 28, 31, 32) . 79 The diagnosis of infant botulism is confirmed by isolation of C. botulinum from the stool, 80 followed by confirmation of toxin production by the mouse neutralization assay (33). 81 Emerging evidence suggests that the genotyping of strains can help to link clustered cases 82 and identify potential shared sources of infections (34) (35) (36) (37) (38) 
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In silico MLST analysis revealed that two of the BoNT/A-carrying isolates shared the same 205 MLST profile (aroE-11, mdh-5, aceK-11, oppB-9, rpoB-8, recA-6, hsp-8) , which represented a 206 new sequence type (ST) that was a 6-locus match to both ST10 and ST53 allele profiles. This 207 profile has been submitted to the PubMLST C. botulinum database and designated ST84.
208
NSW2_A2 contained a new mdh allele sequence which was submitted to the PubMLST C.
209
botulinum database and named mdh-30, the resulting ST profile (aroE-11, mdh-30, aceK-11, 210 oppB-9, rpoB-8, recA-6, hsp-8) was designated ST85. The BoNT/B carrying isolate also had a 211 new , which was a 6-locus match 8, recA-6, hsp-8) the new ST85 represented by NSW3_A2 (aroE-11, mdh-30, aceK-11, oppB-491 9, rpoB-8, recA-6, hsp-8) and the new ST86 represented by NSW4_B6 (aroE-13, mdh-5, aceK-492 11, oppB-9, rpoB-8, recA-6, hsp-8) 
